Topical pain relief:

Indications for: ZINGO

To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.

Adults and Children:

<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.

ZINGO Warnings/Precautions:

Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

ZINGO Classification:

Local anesthetic (amide-type).

ZINGO Interactions:

Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others.

Adverse Reactions:

Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.

Generic Drug Availability:


How Supplied:

Single-use device (disposable, needle-free)—12